adefovir dipivoxil has been researched along with Kidney Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX | 1 |
| Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M | 1 |
| Aschauer, L; Bellwon, P; Bois, F; Crean, D; Dekant, W; Herrgen, K; Hewitt, P; Jennings, P; Leonard, MO; Limonciel, A; Lukas, A; Moenks, K; Schmidt, T; Wilmes, A | 1 |
| Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K | 1 |
| Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S | 1 |
| Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC | 1 |
| Dusak, BA; Goodwin, SD; Kuritzkes, DR; Rooney, JF; Skowron, G; Squires, KE; Stevens, M; Thompson, MA; Tolson, JM; Yuen, GJ | 1 |
| Lok, AS; Tan, J | 1 |
| Arterburn, S; Borroto-Esoda, K; Brosgart, C; Chuck, S; Colombo, M; Hadziyannis, S; Lai, CL; Neuhaus, P; Samuel, D; Schiff, E; Terrault, N; Tillmann, H; Villeneuve, JP; Zeuzem, S | 1 |
1 review(s) available for adefovir dipivoxil and Kidney Diseases
| Article | Year |
|---|---|
Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis.
Topics: Adenine; Creatinine; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseases; Organophosphonates; Risk Factors | 2016 |
2 trial(s) available for adefovir dipivoxil and Kidney Diseases
| Article | Year |
|---|---|
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Lamivudine; Male; Organophosphonates; Oxazines; Pulse Therapy, Drug; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome | 2002 |
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; Humans; Kidney Diseases; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Secondary Prevention; Waiting Lists | 2007 |
7 other study(ies) available for adefovir dipivoxil and Kidney Diseases
| Article | Year |
|---|---|
Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?
Topics: Adenine; Aged; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans; Hypophosphatemia; Kidney Diseases; Male; Middle Aged; Organophosphonates; Osteomalacia | 2019 |
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Hypophosphatemia; Incidence; Kidney Diseases; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Retrospective Studies; Risk Factors; Time Factors | 2014 |
Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing.
Topics: Adenine; Cell Line; Epithelium; Gene Expression Regulation; Humans; Hypoxia; Kidney Diseases; Kidney Tubules, Proximal; Organophosphonates; Oxygen; Protein Array Analysis; Reverse Transcriptase Inhibitors; Toxicity Tests; Xenobiotics | 2015 |
Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Chi-Square Distribution; Female; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Japan; Kidney Diseases; Kidney Tubules, Proximal; Logistic Models; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Odds Ratio; Organic Anion Transport Protein 1; Organophosphonates; Osteomalacia; Polymorphism, Single Nucleotide; Prevalence; Retrospective Studies; Risk Factors; Time Factors | 2015 |
Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Incidence; Kaplan-Meier Estimate; Kidney; Kidney Diseases; Lamivudine; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Organophosphonates; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2012 |
FDA recommends hepatitis B drug.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Approval; Hepatitis B; Humans; Kidney Diseases; Organophosphonates; United States; United States Food and Drug Administration | 2002 |
Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Humans; Kidney Diseases; Lamivudine; Liver Transplantation; Organophosphonates; Secondary Prevention; Tenofovir | 2007 |